Leerink raised the firm’s price target on Oruka Therapeutics (ORKA) to $120 from $109 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics price target raised to $120 from $75 at H.C. Wainwright
- Oruka Therapeutics $700M Secondary priced at $72.50
- Oruka Therapeutics price target raised to $100 from $75 at UBS
- Oruka Therapeutics announces $500M common stock, warrants offering
- Oruka Therapeutics price target raised to $131 from $71 at Clear Street